IP Library Granted Patent US 8,865,745
Granted Patent B2
US 8,865,745 · App. 13/618,026 · Granted Oct 21, 2014

Pyrazolone derivatives as PDE4 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,745
App. No.
13/618,026
Granted
Oct 21, 2014
Kind
B2
Abstract

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

Claims (5)

1. 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-l-yl}-2-oxoethyl)pyrrolidine-2,5-dione.

2. A pharmaceutical composition comprising the compound according to claim 1 together with at least one pharmaceutically acceptable auxiliary.

3. A method for inhibiting type 4 phosphodiesterase in a patient comprising administering to a patient in need thereof the compound according to claim 1 .

4. A method for treating diabetes mellitus in a patient comprising administering to a patient in need thereof the compound according to claim 1 .

5. A method for treating diabetes mellitus type II in a patient comprising administering to a patient in need thereof the compound according to claim 1 .

Assignments (3)
CHANGE OF NAME Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
MERGER Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
MERGER Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →